Compass Therapeutics’ (CMPX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report released on Wednesday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

CMPX has been the subject of several other reports. D. Boral Capital restated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Trading Down 4.8 %

Compass Therapeutics stock opened at $1.77 on Wednesday. The firm has a market cap of $243.53 million, a P/E ratio of -4.78 and a beta of 0.92. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.68. The firm has a 50-day moving average of $1.57 and a 200-day moving average of $1.45.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Research analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Rovin Capital UT ADV bought a new position in Compass Therapeutics during the 3rd quarter valued at about $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics during the third quarter valued at approximately $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics in the third quarter worth approximately $37,000. Cubist Systematic Strategies LLC purchased a new stake in Compass Therapeutics in the second quarter worth approximately $41,000. Finally, SG Americas Securities LLC raised its stake in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares during the last quarter. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.